Safety Reading Notes

Read safety context beside the research guide.

The CBDA and nausea/inflammation source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 30627539

PubMed For Dummies Article

CBDA and nausea/inflammation Evidence Review: the long-form source walk-through

Quick read
  • CBDA and nausea/inflammation currently has 25 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 30627539
  • The evidence classes most visible in the row language are insufficient (12), mechanistic or pharmacological (9), and preclinical (4). PMID 41545891
  • The study-design language most visible in the row language is Animal study (10), Narrative or expert review (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 34115951
  • The repeated topics are nausea-related or inflammation-related outcomes (25), which tells the reader where to start opening PubMed and DOI links. PMID 29057454

Start with the research question

CBDA and nausea/inflammation is built from 25 source-backed evidence row(s) and 25 research source(s). The current evidence classes read as insufficient (12), mechanistic or pharmacological (9), and preclinical (4), and the study-design language most often reads as Animal study (10), Narrative or expert review (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 30627539

The row-level question is not simply whether CBDA and nausea/inflammation is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are nausea-related or inflammation-related outcomes (25). PMID 29057454

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 35984924

Preclinical evidence 4 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32488349

Mechanistic evidence 9 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 31897571

Limits and uncertainty 12 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 23121618

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 26439367

Where this page has the most source density

The largest bucket surfaced for this page is nausea-related or inflammation-related outcomes: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is nausea-related or inflammation-related outcomes: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 30627539

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 29057454

Bucket chapters: what the literature is circling

nausea-related or inflammation-related outcomes: insufficient

12 research sources 12 rows (43-148) Evidence class: insufficient

This bucket summarizes source-backed rows focused on nausea-related or inflammation-related outcomes: insufficient. It currently draws from 12 research source(s), so the exact study type matters. PMID 30627539

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 30627539

  • Evidence row 43

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-relate... PMID 30627539

  • Evidence row 148

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 39667593

nausea-related or inflammation-related outcomes: mechanistic or pharmacological

9 research sources 9 rows (127-146) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on nausea-related or inflammation-related outcomes: mechanistic or pharmacological. It currently draws from 9 research source(s), so the exact study type matters. PMID 29057454

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 29057454

  • Evidence row 127

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nause... PMID 29057454

  • Evidence row 146

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or infla... PMID 32798553

nausea-related or inflammation-related outcomes: preclinical

4 research sources 4 rows (128, 132, 134, 135) Evidence class: preclinical

This bucket summarizes source-backed rows focused on nausea-related or inflammation-related outcomes: preclinical. It currently draws from 4 research source(s), so the exact study type matters. PMID 35984924

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 35984924

  • Evidence row 128

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflam... PMID 35984924

  • Evidence row 132

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflam... PMID 26439367

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (9 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 30627539

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 29057454

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 24595502
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 26381155
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 24012649

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 30627539

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 29057454

Source-reading checklist for CBDA and nausea/inflammation

  1. Open the linked PubMed or DOI record. PMID 35256692
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 37083031
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 30225659
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 36342776
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 32401504

Source Notes

CBDA and nausea/inflammation source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 43

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 30627539

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
  2. Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  3. Evidence row 126

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 34115951

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting.
  4. Evidence row 127

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 29057454

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.
  5. Evidence row 128

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 35984924

    Evidence class: preclinical; Study design: Animal study. Source: Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats.
  6. Evidence row 129

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 32488349

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews.
  7. Evidence row 130

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 31897571

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.
  8. Evidence row 131

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 23121618

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.
  9. Evidence row 132

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 26439367

    Evidence class: preclinical; Study design: Animal study. Source: Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.
  10. Evidence row 133

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: nausea-related or inflammation-related outcomes). PMID 24595502

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
  11. Evidence row 134

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 26381155

    Evidence class: preclinical; Study design: Animal study. Source: Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping.
  12. Evidence row 135

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 24012649

    Evidence class: preclinical; Study design: Animal study. Source: Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid.
  13. Evidence row 136

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 35256692

    Evidence class: insufficient. Source: Short term feeding of industrial hemp with a high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress and inflammation in Holstein steers.
  14. Evidence row 137

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: nausea-related or inflammation-related outcomes). PMID 37083031

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Antiviral activities of hemp cannabinoids.
  15. Evidence row 138

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 30225659

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.
  16. Evidence row 139

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; outcome measure: nausea-related or inflammation-related outcomes). PMID 36342776

    Evidence class: insufficient. Source: Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients.
  17. Evidence row 140

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 32401504

    Evidence class: insufficient. Source: Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis.
  18. Evidence row 141

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 32735381

    Evidence class: insufficient. Source: Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles.
  19. Evidence row 142

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 35807623

    Evidence class: insufficient. Source: Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches.
  20. Evidence row 143

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: nausea-related or inflammation-related outcomes). PMID 25655949

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough.
  21. Evidence row 144

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 32517131

    Evidence class: insufficient; Study design: Narrative or expert review. Source: (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research.
  22. Evidence row 145

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 35629320

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Effects of Cannabidiol on Locomotor Activity.
  23. Evidence row 146

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 32798553

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Behavioural and molecular effects of cannabidiolic acid in mice.
  24. Evidence row 147

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 26030435

    Evidence class: insufficient. Source: Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew).
  25. Evidence row 148

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (outcome measure: nausea-related or inflammation-related outcomes). PMID 39667593

    Evidence class: insufficient. Source: Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid.